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Abstract 
T-cell acute lymphoblastic leukemia is identified in 
10-25% of all newly diagnosed acute lymphoblastic 
leukemia's in children.  The disease results from 
cytogenetic and molecular abnormalities which 
disrupt key oncogenic, tumor suppressor, and 
developmental pathways which control normal 
thymocyte development.  Disruption of key 
pathways alter normal control of cell growth and 
proliferation, along with survival and differentiation. 
This paper provides an update on the cytogenetic and 
molecular basis of pediatric T-cell acute 
lymphoblastic leukemia. 
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Clinics and pathology 
Disease 
Note 
The most common childhood malignancy is acute 
lymphoblastic leukemia (ALL), representing 
approximately one-third of all newly diagnosed 
pediatric malignancies.  Two types of ALL exist, 
those involving B cells and those involving T-cells, 
with T-cell ALL comprising 10-25% of all cases. 
Phenotype/cell stem origin 
T-cells mature in the thymus orchestrate cellular 
immunity, and are integral to the process of humoral 
immunity provided by B-cells.  Early thymic 
progenitors, or lymphoblasts, enter the thymus, and 
in their journey through this organ differentiate by 
the process of somatic rearrangement of T-cell 
receptor (TCR) genes.  The completely 
differentiated T-cell must be both functional and 
self-tolerant, a stringent requirement which results in 
an approximately 95% attrition rate of mature T-
cells.  The approximately 5% that actually leave the 
thymus circulate in the blood as well as through 
lymphatic and non-lymphatic organs [Karrman and 
Johansson, 2017].  T-ALL is, therefore, a neoplasm 
of these lymphoblasts committed to the T-cell 
lineage. 
Etiology 
Because of the relatively low incidence of T-ALL 
compared with B-ALL, there is more data 
specifically regarding the etiology of B-ALL; 
however, the two diseases may share causative 
mechanisms.  Both environmental exposure and 
genetic predisposition have been cited as possible 
etiologies for ALL, with exposure to ionizing 
radiation considered a known risk factor.  The 
inheritance of both rare high penetrance, and more 
common low penetrance alleles, have been 
suggested by several studies, with inherited 
polymorphisms of CDKN2A the only confirmed 
variant directly attributable to an increased risk of 
Pediatric T-Cell Acute Lymphoblastic Leukemia  
 
Atlas Genet Cytogenet Oncol Haematol. 2018; 22(11) 452 
 
developing T-ALL.  In addition, genetic 
predisposition has also been demonstrated in a few 
studies where families have shown a high 
concordance of T-ALL in siblings [Karrman and 
Johansson, 2017].  
 
It is the progressive accumulation of both genetic 
and epigenetic changes involving the immature 
thymocyte within the thymus that leads to T-ALL.  
Approximately half of all patients with T-ALL 
present with chromosome rearrangements that 
involve T-cell receptor genes, most commonly T-
cell receptors α and δ (TRA and TRD, respectively) 
at chromosome band 14q11, T-cell receptor β (TRB) 
at chromosome band 7q34, or T-cell receptor γ 
(TRG) at 7p14.1. Unlike non-malignant conditions 
that give rise to a polyclonal T-cell response, T-cell 
ALL arises from a single cell that gives rise to a 
clone with an identical T-cell receptor gene 
rearrangement.  These rearrangements will juxtapose 
one of these T-cell receptor genes with many critical 
partner genes, many of which code for transcription 
factors.  This results in dysregulation of transcription 
of the partner gene, which is the main driver in 
leukemogenesis. Some of the most common partner 
genes include HOX11 (TLX1) at 10q24, HOX11L2 
(TLX3) at 5q35, MYC at 8q24.1, TCL1 at 14q32, 
TAL1 at 1p32, LMO1 at 11p15, LMO2 at 11p13, 
and LYL1 at 19p13.  As many of these 
rearrangements are submicroscopic, they cannot 
routinely be detected by conventional cytogenetic 
analysis, but require fluorescence in situ 
hybridization (FISH) to confirm the diagnosis.  
Approximately 20% of cases will also demonstrate 
simultaneous rearrangement of IGH@ [Borowitz 
and Chan, 2008].  
 
DNA sequence mutations and copy number variants 
are also identified in T-ALL and are believed to be 
significant contributors to leukemogenesis.  These 
mutations are found in genes involved in the JAK-
STAT and Ras/PI3K/AKT pathways, in epigenetic 
regulation, in mRNA maturation and ribosome 
activity, in modifying histone methylation or 
acetylation, and that function as regulators of 
transcription.  In fact, mutations in epigenetic 
regulators are found in over 50% of pediatric T-ALL 
cases, making this a common mechanism of 
tumorigenesis.  Activating mutations of NOTCH1 
(occurring in at least 60% of T-ALL cases) and loss-
of-function mutations in FBXW7 are also commonly 
found in T-ALL and result in inhibition of ubiquitin-
mediated degradation of the activated form of 
NOTCH1 [Iacobucci and Mullighan, 2017; Karrman 
and Johansson, 2017]. 
Epidemiology 
Approximately 6000 new cases of ALL are 
diagnosed each year in the United States.  T-ALL 
can occur in children or adults, but is more common 
in the pediatric population and more often diagnosed 
in adolescents than in young children, with a median 
age of onset of 9 years, compared with the more 
common precursor B-cell ALL which has an 
incidence peak between 2 and 5 years.  In addition, 
there is a marked male predominance, with boys 
having a threefold-increased risk of developing T-
ALL compared with females.  It is unclear why T-
ALL is primarily a disease of older children and why 
males are more preferentially affected compared 
with B-ALL [Karrman and Johansson, 2017]. 
Clinics 
Both T-ALL and T-cell lymphoblastic lymphoma 
(T-LBL) are aggressive and highly heterogenous 
diseases which originate from genetic and epigenetic 
alterations in immature thymocytes during the 
process of differentiation within the thymus.  T-ALL 
and T-LBL, which demonstrate overlapping clinical, 
morphological and immunophenotypic features, 
have been considered different manifestions of the 
same disease, with the only difference being the site 
of presentation.  T-ALL patients present with 
extensive bone marrow involvement and 
lymphoblasts in peripheral circulation, a mediastinal 
mass in two-thirds of patients, splenomegaly, 
adenopathy, and central nervous system 
involvement. T-LBL is primarily confined to a 
mediastinal mass lesion with minimal or no bone 
marrow involvement. [Burkhardt 2010; Karrman 
and Johansson, 2017].  However, subtle 
immunophenotypic, molecular and cytogenetic 
differences suggest that T-ALL and T-LBL may, in 
fact, be biologically distinct diseases [Burkhardt 
2010; Basso et al, 2011].  
 
T-ALL can present acutely or with symptoms that 
develop and progress over several months. 
Proliferation of the malignant clone in different 
tissues accounts for the common clinical features of 
T-ALL.  Expansion of the clone within the bone 
marrow results in a high leukocyte count and a 
concurrent suppression of normal hematopoiesis, 
resulting in deficiency of normal peripheral blood 
cells, especially thrombocytes.  Symptoms include 
fever, joint and bone pain, recurrent infection, 
lethergy, paleness, mucosal bleeding, and 
hepatosplenomegaly.  CNS involvement results in 
neurological symptoms including headache, visual 
impairment, and nausea. The mediastinal mass seen 
in approximately 50-60% of T-ALL patients can 
cause superior vena cava syndrome. The mediastinal 
mass(s) found in T-LBL predomininately involve the 
anterior mediastinum and cause progressive dyspnea 
with cough, edema, and elevated jugular venous 
pressure. While the clinical manifestations are 
somewhat different, the only true distinguishing 
feature between T-ALL and T-LBL is the blast count 
in bone marrow (>25% blasts in T-ALL). 
[Burkhardt, 2010] 
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Pathology 
The lymphoblasts in B-ALL and T-ALL are 
morphologically indistinguishable from one another, 
necessitating the use of immunophenotyping for 
lineage determination.  ALL blasts are generally of 
intermediate size (up to twice the size of a small 
lymphocyte) with a high nuclear/cytoplasmic ratio, 
although there can be variation in size range.  The 
blasts demonstrate scant, basophilic cytoplasm with 
homogenous and somewhat condensed chromatin. 
Nucleoli may or may not be present depending on 
the size of the blast, as might cytoplasmic vacuoles.  
When the blasts resemble more mature lymphocytes, 
immunophenotyping is required to distinguish T-
ALL from a mature (peripheral) T-cell leukemia 
[Borowitz and Chan, 2008; Onciu M, 2007].  
 
As mentioned, immunophenotyping by 
immunohistochemistry and/or flow cytometry is 
critical in cases of ALL to determine the cell lineage 
(B-cell vs. T-cell).  All T-cell ALLs express CD45 
and cytoplasmic CD3 (CD3 may also be weakly 
expressed on the cell surface), with CD3 being T-cell 
lineage specific and thus an important maker for 
lineage differentiation.  Other T-cell antigens 
consistently expressed include CD2, CD5, and CD7.  
The DNA polymerase terminal deoxynucleotidyl 
transferase (TdT) is expressed in 80-90% of T-ALL 
cases.  In addition, variable expression of CD1, CD4, 
CD8, CD10, and CD56 is observed.  Lineage-
inappropriate expression of myeloid markers 
including CD11b, CD13, CD33, and CD66c are also 
observed; however, their expression is of no 
prognostic significance and do not necessarily 
warrant a diagnosis of biphenotypic leukemia [Onciu 
M, 2007; Karrman and Johansson, 2017].  
 
Because the expression of CDs change with the 
maturation stage of thymocytes, the array of CD 
markers in a case can indicate the stage at which the 
differentiation block occurred.  The stages of 
differentiation include:  1) pro-T (cCD3+, CD7+, 
CD2-, CD1a-, CD34+/-);  2) pre-T (cCD3+, CD7+, 
CD2+, CD1a-, CD34+/-);  3) cortical T (cCD3+, 
CD7+, CD2+, CD1a+,  CD34-); and 4) medullary T 
(cCD3+, CD7+, CD2+, CD1a-, CD34-, surface 
CD3+) [Borowitz and Chan, 2008]. Cases of pro- 
and pre T-ALL tend to have a more inferior outcome 
compared with those designated as cortical or 
medullary T-ALL. The recently delineated category 
of T-ALL known as early T-cell precursor ALL 
(ETP-ALL) has a distinct immunophenotype.  This 
T-ALL demonstrates an immature 
immunophenotype, expresses myeloid and/or stem 
cell markers, and has a poor outcome; however, 
recent studies suggest intensive treatment can 
overcome the poor prognostic outcome in some 
patients [Belver and Ferrando, 2016; Karrman and 
Johansson, 2017]. 
 
This bone marrow aspirate from a 15-year-old boy with 70% marrow involvement by blasts.  The blasts (black 
arrows) were medium size with a high nuclear/cytoplasmic ratio and demonstrated fine chromatin, occasional 
nucleoli and cytoplasmic vacuoles. Giemsa, 1000x 
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The blast population from the same patient expressed the following antigens: CD4 (variable), CD5, CD7, CD8, 
cytoplasmic CD3, cytoplasmic TdT (dim) and cytoplasmic CD1a.  They lacked expression of surface CD3 and 
CD34.  Additionally, the cells expressed CD2, CD10, CD38, and CD45 (dim) which are not shown here.  The 
immunophenotype is consistent with T-acute lymphoblastic leukemia. 
Treatment 
Patients with T-cell ALL generally present with 
more high-risk features than do those with B-ALL.  
These features include an increased resistance to 
chemotherapy, a tendency for earlier relapse, and 
CNS involvement.  Therefore, most patients are 
treated aggressively, including intrathecal 
chemotherapy and CNS radiation therapy.  The 
outcome of children with T-ALL has improved with 
intensification of multimodal therapy. 
Chemotherapy regimens in children with T-ALL 
include initial induction therapy for 4-6 weeks 
followed by intensive combination therapy for 6-8 
months and low-intensity 'anti-metabolite'-based 
therapy for 18-30 months.  Induction therapy 
includes vincristine, a glucocorticoid such as 
dexamethasone, L-asparaginase, and possibly an 
anthracycline such as daunorubicin [Hunger and 
Mullighan, 2015].  
 
Allogeneic hematopoietic stem cell transplantation 
has been found to be an effective treatment for high-
risk T-ALL patients; however, relapse is not 
uncommon in such cases, reducing its curative 
potential.  Continuous monitoring for minimal 
residual disease following transplantation, using 
various molecular methods including qPCR to 
evaluate for fusion transcripts such as SIL/TAL1, is 
critical so that immediate intervention can be 
provided at an early stage of relapse [Zhao et al, 
2017]. 
Prognosis 
The improvement in outcome of children with T-
ALL continues to lag behind its B-cell counterpart.  
With risk-stratified consolidated chemotherapy, 5-
year event free survival for B-ALL stands at 80%  
 
and overall survival at 90%.  However, 5-year event 
free survival and overall survival for T-ALL is just 
over 70% and 80%, respectively.  Patients with T-
ALL have more induction failures and 
extramedullary relapses than those with B-ALL.  
Relapsed T-ALL occurs in up to 25% of children and 
is associated with a much poorer prognosis (30-50% 
survival).  Therefore, monitoring for minimal 
residual disease (MRD), usually by qPCR analysis 
of TCR genes is critical to evaluate the effectiveness 
of treatment [Pui CH et al, 2015; Karrman and 
Johansson, 2017].  If a child continues to have a high 
level of MRD at the end of induction, the risk of 
relapse is high [Chu et al, 2017].  Recent genomic 
studies have begun to uncover the basis for relapse 
in this disease, which appears to involve both clonal 
evolution and selection of genetic variants that drive 
resistence.  One such variant involves mutation in 
the cytosolic 5'-nucleotidase II ( NT5C2) gene which 
are found in 20% of patients with relapsed T-ALL 
[Tzoneva et al, 2013].  In addition, the TFDP3 gene 
has been found to confer chemoresistance in children 
with T-ALL with MRD [Chu et al, 2017]. 
 
Pediatric T-Cell Acute Lymphoblastic Leukemia  
 
Atlas Genet Cytogenet Oncol Haematol. 2018; 22(11) 455 
 
Genetics 
 
Bone marrow cytogenetic evaluation reveals a pericentric inversion of chromosome 7 as well as a del(9q) 
chromosome in a child with T-ALL. 
 
FISH analysis utilizing a TCL1 breakapart probe reveals gene rearrangement identified by seperate red and green 
signals in a patient with T-ALL.  The karyotype also included an additional copy of chromosome 14. 
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FISH analysis utilizing a TCR alpha/delta breakapart probe reveals rearrangement of the locus in a patient with 
T-ALL. 
Cytogenetics 
Note 
Routine karyotyping in T-ALL cases identifies a 
structural chromosome rearrangement, primarily 
translocations and inversions, in 55-75% of patients; 
however, utilization of FISH and/or molecular 
technologies such as single nucleotide 
polymorphism (SNP) array can substantially 
increase diagnostic yield.  The karyotypes in 
pediatric T-ALL are generally near-diploid and are 
rarely complex.  The most common chromosome 
abnormalities identified in T-ALL involve 
rearrangement of one of the T-cell receptor (TCR) 
genes, considered pathognomonic for the disease.  
The T-cell receptor genes that most commonly 
undergo recombination are TRD and TRB, with 
TRA seldom involved and TRG rarely rearranged.  
The rearrangements affecting TCR genes are 
initiated by the normal process of TCR 
recombination, with illegitimate recombination 
occurring when the cellular machinery fails to 
correctly repair the requisite double-strand breaks 
(DSBs) induced by recombination-activating RAG 
proteins [Karrman and Johannson, 2017].  
 
Rearrangements which place a gene with 
transforming capacity next to one of the TCR genes 
enhancers or promoters can result in transcriptional 
dysregulation of the gene, leading to altered 
differentiation and growth.  There are over 30 genes 
that are known to recombine illegitimately with TCR 
genes in T-cell ALL. These genes and their 
associated proteins function primarily as 
transcription factors (oncogenes or tumor 
suppressors), to regulate the cell cycle, as epigenetic 
regulators, as ribosomal proteins, and as signal 
transducers.  
 
A thorough review of cytogenetic aberrations in T-
cell ALL has been published in the ATLAS 
previously by Susana Raimondi [Raimondi, 2007].  
What follows is a summary of the major cytogenetic 
aberrations identified in T-cell ALL.  The reader is 
encouraged to access "T-lineage acute lymphoblastic 
leukemia (T-ALL)" in the ATLAS (Atlas ID 1374) 
for further discussion of these and other 
abnormalities in T-ALL. 
 
Unless otherwise noted, the information is abstracted 
from Raimondi, 2007 and Karrman and Johansson, 
2015: 
Cytogenetics morphological 
t(1;7)(p32;q34) 
Rearranges the TAL1 gene at 1p32 with TRB 
resulting in TAL1 overexpression.  Found in 5% of 
pediatric T-ALL cases. 
t(1;7)(p34;q34) 
Rare abnormality which juxtaposes the LCK 
(lymphocyte-specific protein tyrosine kinase) gene 
at 1p34 with the TRB gene locus at 7q34. There are 
no clear clinical and prognostic correlations. 
t(1;14)(p32;q11.2) 
Juxtaposes the TAL1 gene at 1p32 to TRA/ TRD at 
14q11.2 which downregulates TAL1 expression.  
The rearrangement is found in 10% of childhood T-
ALL. 
TAL1 deletion at 1p32 
Submicroscopic deletions found in 17% of T-ALL 
cases making it the most common rearrangement. 
Results in generation of STIL/TAL1 fusion gene 
leading to overexpression of TAL1.  These patients 
have distinct clinical and biological characteristics 
such as high white blood cell counts, acute tumor 
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lysis syndrome, and disseminated intravascular 
coagulation.  As such, this rearrangement is 
associated with an inferior outcome. 
t(5;14)(q35.1;q32.2) 
Found in 20% of pediatric  and 13% of adult T-ALL 
cases; Juxtaposes the TLX3 gene at 5q35.1 and the 
BCL11B gene at 14q32 resulting in upregulation of 
TLX3.  TLX3-expressing T-ALL is associated with 
an inferior outcome. 
t(6;7)(q23;q34) and del(6q)/MYB gene deletion 
Found in approximately 10% of very young T-ALL 
patients. MYB gene is juxtaposed to TRB resulting 
in upregulation of TRB.  No clear clinical and 
prognostic correlations exist. 
inv(7)(p15.3q34)/t(7;7)(p15.3;q34)/t(7;14)(p15.1;
q11.2)/t(7;14)(p15.1;q32) 
Observed in 1-2% of pediatric T-ALL cases, the 
inv(7) and the t(7;7) place an enhancer of TRB next 
to the HOXA gene cluster at 7p15 resulting in 
upregulation of HOXA genes (especially HOXA10 
and HOXA11). HOXA13 gene is upregulated by 
TRD in the t(7;14)(p15.1;q11.2) and by BCL11B in 
the t(7;14)(p15.1;q32). No clear clinical and 
prognostic significance exist for these 
rearrangements. 
t(7;9)(q34;q34.3) 
A relatively rare abnormality that fuses the 
NOTCH1 gene at 9q34.3 with the TRB gene 
generating a fusion gene resulting in aberrant 
expression of the truncated NOTCH1.  The clinical 
significance of activating mutations of NOTCH1 in 
T-ALL is generally favorable. 
t(7;11)(q34;p13) / >t(7;11)(q34;p15) 
The TRB gene rearranges with either LMO1 at 
11p15 or LMO2 at 11p13 resulting in upregulation 
of these genes.  Found in 5-10% of pediatric T-ALL 
cases. 
t(7;12)(q34;p13.3)/t(12;14)(p13.3;q11) 
These rearrangements result in significant 
upregulation of the CCND2 gene at 12p13.3 through 
rearrangement with either TRB at 7q34 or TRA at 
14q11.  The clinical significance is unknown. 
t(7;19)(q34;p13.2) 
A rare translocation that recombines the LYL1 gene 
at 19p13.2 with TRB resulting in LYL1 
overexpression. T-ALL cases with LYL1 
overexpression demonstrate an immature phenotype 
and a poorer outcome. 
t(8;14)(q24.1;q11.2) 
This abnormality is identified in 2% of patients with 
T-ALL and results in rearrangement of TRA with the 
MYC oncogene at 8q24.1.  The prognosis is 
generally poor. 
del(9p) 
Chromosome 9p deletions are of variable size, but 
generally include 9p21 resulting in loss of two linked 
cyclin-dependent kinase inhibitor genes, CDKN2A 
and CDKN2B. This abnormality is observed in about 
30% of pediatric T-ALL cases by conventional 
analysis and in 80% of cases by FISH.  In 
approximately 50% of these patients, the deletion 
involves both chromosome 9 homologues as the 
result of  segmental uniparental disomy of the 
deleted chromosome.  Inactivation of CDKN2A is 
believed to be a primary abnormality found in 88% 
of younger-age children with T-ALL and to be 
directly involved in T-cell leukemogenesis, while 
loss of CDKN2B is thought to be a secondary 
change.  The prognostic significance of 
del(9p)/CDKN2A deletion does not appear to be 
adverse in pediatric T-ALL. 
ABL1 gene (9q34) amplification 
A cryptic episomal NUP214-ABL1 translocation 
occurs in 6% of mostly pediatric T-ALL cases. This 
is important to diagnose utilizing either ABL1 or 
BCR/ ABL1 FISH probe as malignant clones with 
ABL1 amplification are sensitive to Gleevec®. 
t(10;11)(p12;q14) 
Found in 10% of pediatric T-ALL cases, this 
rearrangement fuses the MLLT10gene at 10p12 with 
the PICALM gene at 11q14 resulting in a specific 
gene expression profile involving upregulation of 
HOXA genes ( HOXA5 and HOXA9); This 
translocation is associated with a poorer prognosis. 
t(10;14)(q24;q11.2) 
Juxtaposes the TLX1 gene at 10q24 to the promoter 
elements of TRA/TRD.  Occurs in 5-10% of 
childhood T-ALL and is associated with favorable 
outcome. 
t(11;14)(p13;q11.2) / t(11;14)(p15;q11.2) 
TRA/TRD at 14q11.2 is juxtaposed to either the 
LMO1 gene at 11p15 or the LMO2 gene at 11p13, 
resulting in gene overexpression.  Another 
mechanism of gene activation includes a cryptic 
deletion of chromosome 11 [del(11)(p12p13)] that 
results in loss of negative regulatory elements 
upstream of LMO2.  Together with translocations, 
these rearrangements are found in 9% of pediatric T-
ALL patients.  The prognostic significance is 
unclear. 
t(11;19)(q23;p13.3) 
This abnormality results in fusion of the MLL 
(official name KMT2A)gene at 11q23 and the 
MLLT1 gene at 19p13.3.  The translocation is found 
in younger patients, especially infants, and is 
associated with high white blood cell count, 
organomegaly, and leukemic involvement of the 
CNS.  While the prognosis is generally adverse, T-
ALL patients with this abnormality often fare better 
than those pateints with MLL rearrangement and a 
B-cell ALL. 
t(12;14)(p13.3;q11.2) 
TRA is translocated to the CCND2 gene at 12p13 
leading to CCND2 upregulation.  This abnormality 
is found in 2-5% of pediatric T-ALL cases. 
inv(14)(q11.2q32.1)/t(14;14)(q11.2;q32.1) 
Both of these abnormalities result in relocation of 
TRA adjacent to the TCL1A oncogene at 14q32.1, 
resulting in its overexpression through interaction 
with the control elements of TRA.   These 
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abnormalities are often found in patients who 
develop T-ALL secondary to ataxia telangiectasia.  
The prognosis of these abnormalities is unknown. 
Uniparental disomy 
Segmental UPD is rare in T-ALL where it is 
observed in <1% of cases, in contrast to its incidence 
of 5-10% in B-cell ALL.  When sUPD is found in 
pediatric T-ALL, it generally involves chromosome 
9p and specifically targets a deleted CDKN2A gene, 
resulting in homozygous CDKN2A deletion. 
Genes involved and 
proteins 
Note 
While many of the cytogenetic and molecular 
abnormalities characteristic of T-cell ALL have been 
known for some time, gene expression profiling and 
various sequencing strategies including exome and 
whole genome sequencing, as well as transcriptome 
analysis, have recently increased our knowledge of 
the molecular pathogenesis of this disease.  Over 100 
genes are now known to be mutated in T-ALL, with 
only NOTCH1 and CDKN2A mutations considered 
to be common events. Recent sequencing studies 
have demonstrated that each case of T-ALL carries 
10-20 biologically relevant mutations, suggesting 
one or a few primary mutations and a number of 
secondary changes that impair the normal 
differentiation and proliferation of T-cells. The 
pattern of these genomic changes is not random, and 
certain specific combinations of genomic mutations 
are found, suggesting an interrelationship of the 
genes responsible for T-cell leukemogenesis.  In 
addition, recent studies have uncovered mutations in 
non-coding regions of DNA that alter transcription 
factors or result in misexpression of micro RNAs and 
long non-coding RNAs, underscoring the fact that 
there is much still to be learned about the 
pathogenesis of T-ALL [Girardi et al, 2017].  
 
Excellent recent reviews of the genes and molecular 
mechanisms involved in T-cell acute lymphoblastic 
leukemia are provided in Belver and Ferrando, 2017 
and Liu et al, 2017.  Much of the information 
provided below was abstracted from these two 
references, as well as the NCBI Reference Sequence 
Database (RefSeq).  Additional references are 
provided as necessary. 
T-cell receptor genes 
TRA (T-cell receptor alpha locus) 
Location 
14q11.2 
TRB (T-cell receptor beta locus) 
Location 
7q34 
TRD (T-cell receptor delta locus) 
Location 
14q11.2 
TRG (T-cell receptor gamma locus) 
Location 
7p14.1 
Genes involved in the NOTCH1 
Pathway 
FBXW7 (F-box and WD repeat 
domaining 7) 
Location 
4q31.3 
Protein 
This gene encodes a member of the F-box protein 
family, which constitute one of the four subunits of 
ubiquitin protein ligase complex that functions in 
phosphorylation-dependent ubiquitination. This 
protein binds directly to cyclin E and probably 
targets cyclin E for ubiquitin-mediated degradation. 
[RefSeq, Mar 2012]. Inactivating mutations of 
FBXW7 are found in 8-30% of T-ALL cases and 
appear to increase the levels of NOTCH1 and MYC 
proteins. 
NOTCH1 (Notch homolog 1, 
translocation-associated 
(Drosophila)) 
Location 
9q34.3 
Protein 
This gene encodes a member of the NOTCH family 
of proteins. Members of this Type I transmembrane 
glycoprotein family share structural characteristics 
including an extracellular domain consisting of 
multiple epidermal growth factor-like (EGF) repeats 
[RefSeq, Jan 2016]. Notch signaling is an 
evolutionarily conserved intercellular signaling 
pathway that transduces extracellular signals to 
affect nuclear genes leading to transcriptional 
changes. NOTCH1 acts as a transcriptional activator, 
regulating the expression of genes involved in 
proliferation, metabolism, and cell cycling such as 
MYC and CCND3.  Constitutive activation of 
NOTCH1 occurs less commonly through the 
t(7;9)(q34;q34.3) and more commonly through 
activating mutations, found in 50% of T-ALL cases. 
Some studies have demonstrated favorable early 
response in children with NOTCH1 mutations; 
however, not all studies have shown improved 
overall survival [Karrman and Johansson, 2017]. 
Oncogenes that function as 
transcription factors 
HOXA@ (Homeobox A cluster 
9/10/11)) 
Location 
7p15.2 
Protein 
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The Hox family of homeodomain transcription 
factors plays an important role in regulating 
hematopoiesis.  Activation of HOXA genes occurs 
often through juxtaposition with the TRB gene in 
either the t(7;7)(p15.3;q34) or inv(7)(p15.3q34) 
(occurring in 3% of T-ALL cases), but other 
molecular mechanisms leading to HOXA 
dysregulation have recently been identified [Bond et 
al, 2016].  The prognostic impact is unknown. 
LMO1 (LIM domain only 1) 
Location 
11p15.4 
Protein 
This locus encodes a transcriptional regulator that 
contains two cysteine-rich LIM domains but lacks a 
DNA-binding domain. LIM domains may play a role 
in protein interactions.  Thus the encoded protein 
may regulate transcription by competitively binding 
to specific DNA-binding transcription factors 
[RefSeq, Jul 2012]. Chromosome rearrangements 
between this locus and either the TRB or TRD gene 
have been observed in 1% T-ALL cases. 
LMO2 (LIM domain only 2) 
Location 
11p13 
Protein 
LMO2 encodes a cysteine-rich, two LIM-domain 
protein that is required for yolk sac erythropoiesis. 
The LMO2 protein has a critical role in 
hematopoietic development and is highly conserved. 
The transcription start site is located approximately 
25 kb downstream from the 11p13 T-cell 
translocation cluster where a number of T-cell ALL 
specific translocations occur [RefSeq, Nov 2008].  
Depending on the specific cytogenetic abnormality, 
the LMO2 gene is involved in 1-6% of T-ALL cases. 
LYL1 (LYL1, basic helix-loop-helix 
family member) 
Location 
19p13.13 
Protein 
This gene codes for a basic helix-loop-helix 
transcription factor that plays a role in blood vessel 
maturation and in hematopoeisis [RefSeq, Sep 
2010].  Disruption is caused by the 
t(7;19)(q34;p13.2) which involves the TRB gene, 
and is observed in 1% of T-cell ALL cases. 
MLLT10 (MLLT10, histone lysine 
methyltransferase DOT1L cofactor) 
Location 
10p12.31 
Protein 
This gene encodes a transcription factor.  It fuses 
with the PICALM gene at 11q14 resulting in a 
specific gene expression profile involving 
upregulation of HOXA genes (HOXA5 and 
HOXA9) that is associated with a poorer prognosis. 
MYB (MYB proto-oncogene, 
transcription factor) 
Location 
6q23.3 
Protein 
The MYB protein functions as a transcription 
regulator and plays an essential role in the regulation 
of hematopoiesis. Upregulation of MYB through a 
chromosome 6q deletion or the t(6;7)(q23 q34) 
which occurs in 3% of all T-ALL cases and in 10% 
of very young T-ALL patients 
MYC (MYC proto-oncogene, bHLH 
transcription factor) 
Location 
8q24.21 
Protein 
This gene is a proto-oncogene that encodes a nuclear 
phosphoprotein that plays a role in cell cycle 
progression, apoptosis and cellular transformation in 
many cancers. The encoded protein regulates the 
transcription of specific target genes [RefSeq, Aug 
2017]. MYC is also an important mediator of 
NOTCH1 induced transformation is dysregulated in 
the t(8;14)(q24.1;q11.2) which involves the TRA 
gene, and generally predicts a poor prognosis in T-
ALL. 
NKX2-1 (NK2 homeobox 1) 
Location 
14q13.3 
Protein 
The NKX2-1 homeobox gene is one of a number of 
genes including TLX1, TLX3, and NKX2-5 which 
encode transcription factors that are physiologically 
silent during hematopoiesis, but which undergo 
ectopic activation in transformed thymocytes [Nagel 
et al, 2017].  T-ALLs with NKX2-1 mutations share 
a gene expression signature similar to cases with 
TLX1 expression and show arrest of an early cortical 
stage of thymocyte development. Aberrant 
expression of the gene occurs with the 
inv(14)(q11.2q13), inv(14)(q13q32.33), and 
t(7;14)(q34;q13), and is found in 5% of pediatric T-
ALL cases. 
TAL1 (TAL bHLH transcription factor 
1, erythroid differentiation factor) 
Location 
1p33 
Protein 
The TAL1 protein is a basic helix-loop-helix 
transcription factor that plays an essential role in 
regulating normal hematopoiesis.  Upregulation of 
the TAL1 gene occurs by means of submicroscopic 
chromosome 1p deletion, insertions, or disruption of 
chromatin structure resulting in SIL-TAL1 fusion.  
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Recent evidence demonstrates that TAL1 is, in fact, 
a master transcription factor in the 'core regulatory 
circuit' which includes TAL1, LMO2, RUNX1, 
GATA2, and FLI1 genes that function to reinforce 
and stabilize gene expression programs via 
'interlocking' regulatory loops [Sanda and Leong, 
2017].  Translocations of TAL1 are found in 1-3% 
of T-ALL cases while deletions are identified in up 
to 25% of cases.  The prognostic significance of the 
SIL-TAL1 fusion gene is unclear, with some studies 
demonstrating a poorer outcome while others 
showed no significance (Karrman and Johannson, 
2017]. 
TAL2 (TAL bHLH transcription factor 
2) 
Location 
9q31.2 
Protein 
This intronless gene encodes a helix-loop-helix 
protein and is activated by the t(7;9)(q34;q32) 
involving the TRB gene, found in about 1% of  
pediatric T-ALL cases. 
TLX1 (HOX11) (T-cell leukemia 
homeobox 1) 
Location 
10q24.31 
Protein 
This gene encodes a nuclear transcription factor that 
belongs to the NK-linked or NK-like (NKL) 
subfamily of homeobox genes. The TLX1 protein is 
required for normal development of the spleen 
during embryogenesis and specifies neuronal cell 
fates [RefSeq, Sep 2010].   The t(10;14)(q24;q11.2) 
juxtaposes the TLX1 gene with the promoter 
elements of TRA/TRD and is found in 5-10% of 
pediatric T-ALL cases.  There appears to be no 
prognostic impact in pediatric T-ALL. 
TLX3 (HOX11L2) (T-cell leukemia 
homeobox 3) 
Location 
5q35.1 
Protein 
The TLX3 protein is an orphan homeobox protein 
that encodes a DNA-binding nuclear transcription 
factor. Upregulation of TLX3 through juxtaposition 
of the gene with strong T-cell regulatory elements in 
the BCL11B locus at 14q32 occurs in 20-25% of 
pediatric T-ALL cases and is associated with an 
inferior outcome. 
Tumor suppressor genes that 
function as transcription factors 
BCL11B (B-cell CLL/lymphoma 11b) 
Location 
14q32.2 
Protein 
This gene encodes a C2H2-type zinc finger protein. 
Although the specific function of this gene has not 
been determined, the protein is known to be a 
transcriptional repressor [RefSeq, Aug 2013].  
Inactivating mutation or deletion of BCL11B is 
found in 10% of T-ALL cases. There appears to be 
no prognostic impact in pediatric T-ALL. 
ETV6 (ETS variant 6) 
Location 
12p13.2 
Protein 
This gene encodes an ETS family transcription 
factor required for development of hematopoietic 
stem cells   Inactivating mutation or deletion of 
ETV6 is found in 13% of T-ALL cases. 
GATA3 (GATA binding protein 3) 
Location 
10p14 
Protein 
This gene encodes a protein which belongs to the 
GATA family of transcription factors. The protein is 
an important regulator of T-cell differentiation and 
plays a crucial role in the development of early T-
cell progenitors.  The gene is mutated in early T-cell 
precursor T-ALL.  Inactivating mutation or deletion 
is observed in 5% of T-ALL cases. 
LEF1 (Lymphoid enhancer binding 
factor 1) 
Location 
4q25 
Protein 
This gene encodes a transcription factor that binds to 
a functionally important site in the T-cell receptor-
alpha enhancer, thereby conferring maximal 
enhancer activity, and is a key mediator of WNT 
signaling. T-ALL with LEF1 mutations demonstrate 
high levels of MYC expression and appear to arrest 
at the early cortical thymocyte stage.  Inactivating 
mutation or deletion of LEF1 is found in 10-15% of 
T-ALL cases. 
RUNX1 (Runt related transcription 
factor 1) 
Location 
21q22.12 
Protein 
The protein encoded by this gene represents the 
alpha subunit of core binding factor (CBF), a 
heterodimeric transcription factor that binds to the 
core element of many enhancers and promoters.  
CBF and is thought to play a prominent role in the 
development of normal hematopoiesis [RefSeq, Jul 
2008].   Inactivating mutation or deletion of RUNX1 
is found in 10-20% of T-ALL cases. 
WT1 (Wilms tumor 1) 
Location 
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11p13 
Protein 
This gene encodes a transcription factor that appears 
to play a role in hematopoiesis to maintain primitive 
stem cell quiescence and to promote differentiation 
of mature progenitors.  Inactivating mutation or 
deletion of WT1 is found in 10% of T-ALL cases. 
Cell cycle regulatory genes 
CDKN2A (Cyclin dependent kinase 
inhibitor 2A) 
Location 
9p21.3 
Protein 
Inactivation of CDKN2A is believed to be a primary 
abnormality found in 88% of younger-age children 
with T-ALL and to be directly involved in T-cell 
leukemogenesis.  This gene encodes protein 
isoforms including, p16INK4A and p14ARF, that 
function as negative regulators of the cell cycle by 
inhibiting CDK4 kinase to inhibit cell cycle G1 
progression. Another specific isoform functions to 
stabilize TP53 as it can interact with, and sequester, 
the E3 ubiquitin-protein ligase MDM2, a protein 
responsible for the degradation of p53 [RefSeq, Sep 
2012].  Chromosome 9p deletions can inactivate 
CDKN2A, an abnormality found in about 30% of 
pediatric T-ALL cases by conventional analysis and 
in 80% of cases by FISH.  In approximately 50% of 
these patients, the deletion involves both 
chromosome 9 homologues, often through 
segmental uniparental disomy.  CDKN2A loss often 
occurs together with activating mutations of 
NOTCH1. 
CDKN2B (Cyclin dependent kinase 
inhibitor 2B) 
Location 
9p21.3 
Protein 
This gene lies adjacent to CDKN2A in a region that 
is frequently mutated and deleted in a wide variety 
of tumors.  The gene encodes a cyclin-dependent 
kinase inhibitor that prevents the activation of CDK 
kinases, resulting in negative regulation of cell cycle 
G1 progression [RefSeq, Jul 2008].  Chromosome 9p 
deletions resulting in loss of CDKN2B as well as 
CDKN2A are observed in about 30% of pediatric T-
ALL cases by conventional analysis and in 80% of 
cases by FISH.  In approximately 50% of these 
patients, the deletion involves both chromosome 9 
homologues. Loss of CDKN2B is thought to be a 
secondary change. 
RB1 (RB transcriptional corepressor 
1) 
Location 
13q14.2 
Protein 
The RB1 protein is a negative regulator of the cell 
cycle that stabilizes constitutive heterochromatin to 
maintain overall chromatin structure. The active, 
hypophosphorylated form of the protein binds 
transcription factor E2F to downregulate 
transcription of S phase genes [RefSeq, Jul 2008].  
RB1 deletion is identified in 12% of pediatric T-ALL 
cases. 
Assembly protein 
PICALM (Phosphatidylinositol 
binding clathrin assembly protein) 
Location 
11q14.2 
Protein 
This gene encodes a clathrin assembly protein which 
recruits clathrin and adaptor protein complex 2 
(AP2) to cell membranes and may determine the 
amount of membrane to be recycled [RefSeq, May 
2011].  The t(10;11)(p12;q14) fuses the MLLT10 
gene at 10p12 with the PICALM gene, resulting in a 
specific gene expression profile involving 
upregulation of HOXA genes (HOXA5, HOXA9, 
and HOXA19) found in 10% of pediatric T-ALL 
cases.  The rearrangement is associated with a poorer 
prognosis. 
Signal transduction genes 
ABL1 (ABL proto-oncogene 1, non-
receptor tyrosine kinase) 
Location 
9q34.12 
Protein 
This gene is a protooncogene that encodes a protein 
tyrosine kinase involved in cell division, adhesion, 
differentiation, and response to stress. The protein's 
SH3 domain negatively regulates its activity, 
whereby deletion of the region encoding this domain 
results in an oncogene. The ubiquitously expressed 
protein has DNA-binding activity regulated by 
CDC2-mediated phosphorylation, suggesting a cell 
cycle function [RefSeq, Aug 2014].  Amplification 
of  9q34 resulting from cryptic episomal NUP214-
ABL1 translocation occurs in 6% of mostly pediatric 
T-ALL cases.  This is an important diagnosis to 
make with either ABL1 or BCR/ABL1 FISH probe, 
as malignant clones with ABL1 amplification are 
sensitive to Gleevec®. 
FLT3 (fms related tyrosine kinase 3) 
Location 
13q12.2 
Protein 
This gene encodes a receptor tyrosine kinase that 
regulates hematopoiesis. This receptor protein is 
activated by binding of the fms-related tyrosine 
kinase 3 ligand to the extracellular domain resulting 
in autophosphorylation of the receptor. The activated 
receptor kinase then phosphorylates and activates 
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multiple cytoplasmic effector molecules in pathways 
involved in apoptosis, proliferation, and 
differentiation of hematopoietic cells in bone 
marrow. [RefSeq, Jan 2015].  Activating mutations 
are identified in 5-10% of T-ALL cases. 
IL7R (Interleukin 7 receptor) 
Location 
5p13.2 
Protein 
The IL7R gene encodes a protein receptor for 
interleukin 7 (IL7) that has been shown to activate 
the JAK-STAT signalling pathway. The protein has 
been shown to play a critical role in V(D)J 
recombination during lymphocyte development.  
Inactivating mutations are found in 10% of T-ALL 
cases.  Mutations of IL7R are particularily prevelant 
in ETP T-ALL. 
JAK1 (Janus kinase 1) 
Location 
1p31.3 
Protein 
This gene encodes a membrane protein tyrosine 
kinase. The kinase phosphorylates STAT proteins 
(signal transducers and activators of transcription) 
and plays a key role in interferon-alpha/beta and 
interferon-gamma signal transduction. [RefSeq, Mar 
2016].  Activating mutations are found in 4-18% of 
T-ALL cases. 
JAK3 (Janus kinase 3) 
Location 
19p13.11 
Protein 
The gene encodes a tyrosine kinases involved in 
cytokine receptor-mediated intracellular signal 
transduction. It is predominantly expressed in 
immune cells and transduces a signal in response to 
its activation via tyrosine phosphorylation by 
interleukin receptors. [RefSeq, Jul 2008].  Activating 
mutations are found in 7% of T-ALL cases. 
NUP214 (Nucleoporin 214) 
Location 
9q34.13 
Protein 
The nuclear pore complex extends across the nuclear 
envelope and forms a gateway that regulates the flow 
of macromolecules between the nucleus and the 
cytoplasm. This gene is a member of the FG-repeat-
containing nucleoporins, which are the main 
components of the nuclear pore complex in 
eukaryotic cells. The NUP214 protein is localized to 
the cytoplasmic face of the nuclear pore complex 
where it is required for proper cell cycle progression 
and nucleocytoplasmic transport [RefSeq, Dec 
2015].  NUP214 fuses with ABL1 resulting in 
episomal ABL1 amplification observed in 5% of T-
ALL cases.  A SET-NUP214 fusion is also identified 
in T-ALL as the result of a 3Mb deletion between the 
SET locus at 9q34.11 and the NUP214 locus.  This 
is found in 3% of T-ALL cases. 
PTEN (Phosphatase and tensin 
homolog) 
Location 
10q23.31 
Protein 
The PTEN protein is a phosphatidylinositol-3,4,5-
trisphosphate 3-phosphatase that functions as a 
tumor suppressor by negatively regulating 
AKT/PKB signaling pathway .  Inactivating 
mutations or deletions of PTEN occur in 10-15% of 
T-ALL cases. 
Genes involved in epigenetic 
regulation  
EED (Embryonic ectoderm 
development) 
Location 
11q14.2 
Protein 
This gene encodes a member of the Polycomb-group 
(PcG) family. PcG family members form multimeric 
protein complexes involved in maintaining the 
transcriptional repressive state of genes by histone 
deacetylation [RefSeq, Jul 2008].  Inactivating 
mutations and deletions are identified in 10% of T-
ALL cases. 
EZH2 (Enhancer of zeste 2 polycomb 
repressive complex 2 subunit) 
Location 
7q36.1 
Protein 
This gene encodes a member of the Polycomb-group 
(PcG) family. PcG family members form multimeric 
protein complexes which are involved in 
maintaining the transcriptional repressive state of 
genes over successive cell generations. The protein 
associates with the embryonic ectoderm 
development protein, the VAV1 oncoprotein, and 
the X-linked nuclear protein. [RefSeq, Feb 2011].  
Inactivating mutations and deletions are identified in 
10-15% of T-ALL cases. 
KDM6A (Lysine demethylase 6A) 
Location 
Xp11.3 
Protein 
This gene encodes a protein which contains a JmjC-
domain and catalyzes the demethylation of 
tri/dimethylated histone H3 [RefSeq, Apr 2014]. 
Inactivating mutations and deletions are identified in 
5-15% of T-ALL cases. 
PHF6 (PHD finger protein 6) 
Location 
Xq26.2 
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Protein 
This gene is a member of the plant homeodomain 
(PHD)-like finger (PHF) family. It encodes a protein 
with two PHD-type zinc finger domains, indicating 
a potential role in transcriptional regulation that 
localizes to the nucleolus [RefSeq, Jun 2010]. 
Inactivating mutations and deletions are identified in 
16% of pediatric T-ALL cases. 
SUZ12 (SUZ12 polycomb repressive 
complex 2 subunit) 
Location 
17q11.2 
Protein 
This zinc finger gene encodes a protein with a zinc 
finger domain in the C terminus of the coding region.  
Inactivating mutations and deletions are identified in 
10% of T-ALL cases. 
Transcriptional coactivator gene 
KMT2A (Lysine methyltransferase 
2a)/MLL (mixed lymphoid leukemia) 
Location 
11q23.3 
Protein 
This gene encodes a transcriptional coactivator that 
plays an essential role in regulating gene expression 
during hematopoiesis and hematopoiesis. The 
KMT2A protein contains multiple conserved 
functional domains. One of these domains, the SET 
domain mediates chromatin modifications 
associated with epigenetic transcriptional activation. 
Processing of the protein by the enzyme Taspase 1 
splits it into two fragments. These fragments 
reassociate and further assemble into different 
multiprotein complexes that regulate the 
transcription of specific target genes, including 
many of the HOX genes [RefSeq, Oct 2010].  A 
t(11;19)(q23;p13) fuses KMT2A with MLLT1 in 5% 
of T-ALL cases. 
Ribosomal protein gene  
RPL10 (Ribosomal protein L10) 
Location 
Xq28 
Protein 
This gene encodes a ribosomal protein that is a 
component of the 60S ribosome subunit.  Mutations 
are found in 6% of pediatric T-ALL cases 
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